Collegium Pharmaceutical (NASDAQ:COLL) had its price objective boosted by Jefferies Group to $32.00 in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 35.48% from the company’s previous close.
Other analysts have also recently issued research reports about the company. Piper Jaffray Companies set a $23.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, December 14th. Needham & Company LLC lifted their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Monday, November 13th. Finally, BidaskClub cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.17.
Collegium Pharmaceutical (NASDAQ COLL) traded up $1.85 during trading on Monday, hitting $23.62. The stock had a trading volume of 1,908,695 shares, compared to its average volume of 619,791. The firm has a market cap of $769.12 and a PE ratio of -7.95. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $26.77.
Several hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors lifted its holdings in shares of Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares during the period. Royal Bank of Canada lifted its holdings in shares of Collegium Pharmaceutical by 12.7% in the 2nd quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 3,285 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Collegium Pharmaceutical by 87.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares during the period. Teton Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 18.5% in the 4th quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after buying an additional 5,000 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after buying an additional 5,136 shares during the period. 82.40% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group Increases Collegium Pharmaceutical (COLL) Price Target to $32.00” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/jefferies-group-increases-collegium-pharmaceutical-coll-price-target-to-32-00.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.